This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Meta-Analysis

Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials

Christoph U. Correll, MD; Lawrence Maayan, MD; John Kane, MD; Marc De Hert, MD, PhD; and Dan Cohen, MD, PhD

Published: June 22, 2016

Article Abstract

Objective: To meta-analyze the efficacy and tolerability of topiramate-antipsychotic cotreatment in schizophrenia.

Data Sources: PubMed/MEDLINE database were searched until September 5, 2015, using the keywords topiramate AND antipsych* OR neurolept* OR specific antipsychotic names.

Study Selection: Randomized controlled trials (RCTs) of topiramate-antipsychotic cotreatment versus placebo and ongoing antipsychotic treatment in patients with schizophrenia spectrum disorders were included.

Data Extraction: Two evaluators extracted data. Standardized mean difference (SMD), weighted mean difference (WMD), and risk ratio (RR) ± 95% CIs were calculated.

Results: In 8 RCTs, lasting a mean ± SD of 13.6 ± 4.9 weeks, 439 patients were randomized to topiramate (100-400 mg/d) versus placebo (trials = 7) or ongoing antipsychotic treatment (trial = 1). Topiramate outperformed the comparator regarding total psychopathology (trials = 6, n = 269, SMD = 0.57 [95% CI, 1.01 to 0.14], P = .01), positive symptoms (trials = 4, n = 190, SMD = 0.56 [95% CI, 1.0 to 0.11], P = .01), negative symptoms (trials = 4, n = 190, SMD = 0.62 [95% CI, 1.13 to 0.10], P = .02) general psychopathology (trials = 3, n = 179, SMD = 0.69 [95% CI, 1.27 to 0.11], P = .02), body weight (trials = 7, n = 327, WMD = 3.14 kg [95% CI, 5.55 to 0.73], P = .01), and body mass index (BMI) (trials = 4, n = 198, WMD = 1.80 [95% CI, 2.77 to 0.84], P = .0003). Topiramate’s efficacy for total psychopathology and weight reduction effects were not mediated/moderated by trial duration, topiramate dose, sex, age, inpatient status, baseline Positive and Negative Syndrome Scale, or baseline BMI. Conversely, clozapine-topiramate cotreatment moderated greater efficacy, but less weight loss, compared to topiramate-nonclozapine antipsychotic combinations. All-cause discontinuation was similar between topiramate and control groups (trials = 7, RR = 1.24 [95% CI, 0.76 to 2.02], P = .39). Topiramate trended only toward more paresthesia than placebo (trials = 4, RR = 2.03 [95 % CI, 0.99 to 4.18], P = .05).

Conclusions: Topiramate-antipsychotic cotreatment significantly reduced total, positive, negative, and general psychopathology and weight/BMI in patients with schizophrenia spectrum disorder while being well tolerated. However, larger studies are needed to confirm and extend these findings.

Volume: 77

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Skeletal and Dental Fractures Associated With Electroconvulsive Therapy

Recent data suggest the risk of skeletal or dental fracture with ECT may be as low as...

Read More...